Incannex Healthcare (IXHL) Competitors $0.21 +0.00 (+1.01%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.21 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IXHL vs. ENLV, GBIO, TPST, DARE, SNYR, CARA, PASG, CVKD, TENX, and CYTHShould you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Enlivex Therapeutics (ENLV), Generation Bio (GBIO), Tempest Therapeutics (TPST), Dare Bioscience (DARE), Synergy CHC (SNYR), Cara Therapeutics (CARA), Passage Bio (PASG), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. Incannex Healthcare vs. Its Competitors Enlivex Therapeutics Generation Bio Tempest Therapeutics Dare Bioscience Synergy CHC Cara Therapeutics Passage Bio Cadrenal Therapeutics Tenax Therapeutics Cyclo Therapeutics Incannex Healthcare (NASDAQ:IXHL) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Do institutionals and insiders believe in IXHL or ENLV? 0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 15.5% of Incannex Healthcare shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend IXHL or ENLV? Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 751.06%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk & volatility, IXHL or ENLV? Incannex Healthcare has a beta of 7.47, indicating that its share price is 647% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Does the media refer more to IXHL or ENLV? In the previous week, Incannex Healthcare had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 2 mentions for Incannex Healthcare and 0 mentions for Enlivex Therapeutics. Incannex Healthcare's average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score. Company Overall Sentiment Incannex Healthcare Neutral Enlivex Therapeutics Neutral Which has stronger earnings and valuation, IXHL or ENLV? Enlivex Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncannex Healthcare$10K615.09-$18.46M-$1.21-0.17Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.78 Is IXHL or ENLV more profitable? Enlivex Therapeutics' return on equity of -57.67% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Incannex HealthcareN/A -342.92% -148.64% Enlivex Therapeutics N/A -57.67%-50.52% SummaryEnlivex Therapeutics beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks. Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXHL vs. The Competition Export to ExcelMetricIncannex HealthcareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.16M$2.43B$5.54B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-0.178.9827.4320.23Price / Sales615.09682.84422.11118.64Price / CashN/A158.5936.8958.07Price / Book1.164.588.045.67Net Income-$18.46M$31.34M$3.18B$249.13M7 Day Performance2.80%3.25%2.89%3.28%1 Month Performance16.76%7.08%3.70%5.56%1 Year Performance-92.45%0.17%36.15%21.12% Incannex Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXHLIncannex Healthcare0.3213 of 5 stars$0.21+1.0%N/A-92.4%$6.16M$10K-0.173News CoverageENLVEnlivex Therapeutics3.1894 of 5 stars$1.16+6.4%$10.00+762.1%-11.7%$25.78MN/A-1.7670GBIOGeneration Bio2.9795 of 5 stars$0.36-5.3%$7.33+1,937.6%-85.7%$25.47M$24.56M-0.33150TPSTTempest Therapeutics1.7943 of 5 stars$6.85+1.0%$30.00+338.0%-74.0%$24.97MN/A-0.3820News CoverageDAREDare Bioscience1.6094 of 5 stars$2.56-9.2%$12.00+368.8%-22.3%$24.96M$10K-15.0630News CoverageHigh Trading VolumeSNYRSynergy CHC3.7715 of 5 stars$2.57-3.0%$10.00+289.1%N/A$24.36M$34.83M0.0040Gap UpCARACara Therapeutics0.354 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumePASGPassage Bio3.079 of 5 stars$0.33-14.4%$7.50+2,140.1%-48.3%$24.30MN/A-0.33130Gap UpCVKDCadrenal Therapeutics3.042 of 5 stars$11.44-7.4%$32.00+179.7%N/A$24.29MN/A-1.244Gap DownTENXTenax Therapeutics1.3 of 5 stars$5.62-2.9%$17.50+211.4%+87.4%$24.02MN/A-2.279CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Generation Bio Alternatives Tempest Therapeutics Alternatives Dare Bioscience Alternatives Synergy CHC Alternatives Cara Therapeutics Alternatives Passage Bio Alternatives Cadrenal Therapeutics Alternatives Tenax Therapeutics Alternatives Cyclo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IXHL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incannex Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
